Table 2. Associations between AGR and clinicopathological characteristics in primary cohort patients before and after PSM.
| Variable | Pre-PSM | Post-PSM | ||||
|---|---|---|---|---|---|---|
| AGR ≤ 1.22 (n = 72) | AGR > 1.22 (n = 344) | P value | AGR ≤ 1.22 (n = 52) | AGR > 1.22 (n = 52) | P value | |
| Age (years) | < 0.001* | 0.695 | ||||
| ≤ 60 | 29 (40.8 %) | 232 (67.4 %) | 24 (46.2 %) | 26 (50.0 %) | ||
| > 60 | 42 (59.2 %) | 112 (32.6 %) | 28 (53.8 %) | 26 (50.0 %) | ||
| Sex | 0.399 | 0.543 | ||||
| Male | 41 (57.7 %) | 217 (63.1 %) | 31 (59.6 %) | 34 (65.4 %) | ||
| Female | 30 (42.3 %) | 127 (36.9 %) | 21 (40.4 %) | 18 (34.3 %) | ||
| T stage | < 0.001* | |||||
| 1 | 42 (59.2 %) | 295 (86.3 %) | 40 (76.9 %) | 37 (71.1 %) | 0.468 | |
| 2 | 12 (16.9 %) | 32 (9.4 %) | 8 (15.4 %) | 7 (13.5 %) | ||
| 3 | 17 (23.9 %) | 15 (4.4 %) | 4 (7.7 %) | 8 (15.4 %) | ||
| N stage | 0.005* | |||||
| 0 | 66 (93.0 %) | 339 (98.5 %) | 50 (96.2 %) | 50 (96.2 %) | 1 | |
| 1 | 5 (7.0 %) | 5 (1.5 %) | 2 (3.8 %) | 2 (3.8 %) | ||
| Fuhrman grade | ||||||
| 1 | 8 (11.8 %) | 77 (23.1 %) | 6 (13.3 %) | 1 (2.2 %) | ||
| 2 | 30 (44.1 %) | 170 (50.9 %) | 0.001* | 25 (55.6 %) | 25 (55.6 %) | 0.228 |
| 3 | 20 (29.4 %) | 74 (22.2 %) | 11 (24.4 %) | 15 (33.3 %) | ||
| 4 | 10 (14.7 %) | 13 (3.9 %) | 3 (6.7 %) | 4 (8.9 %) | ||
| Tumor size, cm | ||||||
| ≤ 5 | 30 (42.9 %) | 235 (68.5 %) | < 0.001* | 28 (53.8 %) | 31 (59.6 %) | 0.553 |
| > 5 | 40 (57.1 %) | 108 (31.5 %) | 24 (46.2 %) | 21 (40.4 %) | ||
| Tumor necrosis | < 0.001* | 0.426 | ||||
| Absent | 56 (78.9 %) | 319 (92.7 %) | 45 (86.5 %) | 42 (80.8 %) | ||
| Present | 15 (21.1 %) | 25 (7.3 %) | 7 (13.5 %) | 10 (19.2 %) | ||
| LVI | 0.001* | 0.462 | ||||
| Absent | 62 (87.3 %) | 332 (96.5 %) | 49 (94.2 %) | 47 (90.4 %) | ||
| Present | 9 (12.7 %) | 12 (3.5 %) | 3 (5.8 %) | 5 (9.6 %) | ||
| Hemoglobin (g/L) | < 0.001* | 0.631 | ||||
| ≤ LLN | 27 (38.6 %) | 22 (6.4 %) | 12 (23.1 %) | 10 (19.2 %) | ||
| > LLN | 43 (61.4 %) | 321 (93.6 %) | 40 (76.9 %) | 42 (80.8 %) | ||
| AKP | < 0.001* | 1 | ||||
| ≤ ULN | 62 (87.3 %) | 334 (98.2 %) | 48 (92.3 %) | 48 (92.3 %) | ||
| > ULN | 9 (12.7 %) | 6 (1.8 %) | 4 (7.7 %) | 4 (7.7 %) | ||
| LDH | 0.005* | 0.315 | ||||
| ≤ 1.5*ULN | 67 (94.4 %) | 337 (99.1 %) | 52 (100.0 %) | 51 (98.1 %) | ||
| > 1.5*ULN | 4 (5.6 %) | 3 (0.9 %) | 0 (0.0 %) | 1 (1.9 %) | ||
| BMI (Kg/ m2) | ||||||
| ≤ 18.5 | 28 (38.9 %) | 15 (4.4 %) | 22(42.3 %) | 13 (25.0 %) | ||
| 18.5–24.5 | 29 (40.3 %) | 284 (82.5 %) | < 0.001* | 20 (38.5 %) | 29 (55.8 %) | 0.138 |
| > 24.5 | 14 (19.4 %) | 42 (12.2 %) | 10 (19.2 %) | 10 (19.2 %) | ||
* p < 0.05
Abbreviations: PSM, propensity score matching; LLN, lower limit of normal; ULN, upper limit of normal; LVI, lymphovascular invasion; AKP, alkaline phosphatase; LDH, lactate dehydrogenase; BMI, body mass index; AGR, albumin to globulin ratio.